Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 2.7.1.153 extracted from

  • Farghaly, H.S.; Blagbrough, I.S.; Medina-Tato, D.A.; Watson, M.L.
    Interleukin 13 increases contractility of murine tracheal smooth muscle by a phosphoinositide 3-kinase p110delta-dependent mechanism (2008), Mol. Pharmacol., 73, 1530-1537.
    View publication on PubMed

Activating Compound

Activating Compound Comment Organism Structure
interleukin-13 treatment of tracheal tissue is associated with an early activation of phosphoinositide 3-kinase Mus musculus

Protein Variants

Protein Variants Comment Organism
D910A site-directed mutagenesis of isoform p110delta, catalytically inactive. Interleukin is unable to induce hyper-responsiveness in tissues expressing the mutant Mus musculus

Inhibitors

Inhibitors Comment Organism Structure
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one i.e. LY294002, treatment prevents interleukin-13-induced hyper-responsiveness Mus musculus
2-(6-aminopurin-9-ylmethyl)-5-methyl-3-O-tolyl-3H-quinazolin-4-one i.e.IC87114, selective for isoform p110delta. Treatment prevents interleukin-13-induced hyper-responsiveness Mus musculus
Wortmannin treatment prevents interleukin-13-induced hyper-responsiveness Mus musculus

Organism

Organism UniProt Comment Textmining
Mus musculus
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
smooth muscle tracheal smooth muscle Mus musculus
-